(Q44050707)

29 November 2017

title

Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. (English)

1 reference

experimental autoimmune encephalomyelitis

29 November 2017

main subject

0 references

9

Richard M Ransohoff

1 reference

29 November 2017

Masaru Matsui

1

1 reference

29 November 2017

Jennifer Weaver

2

1 reference

29 November 2017

Amanda E I Proudfoot

3

1 reference

29 November 2017

Jerome R Wujek

4

1 reference

29 November 2017

Tao Wei

5

1 reference

29 November 2017

Edward Richer

6

1 reference

29 November 2017

Bruce D Trapp

7

1 reference

29 November 2017

Ashwin Rao

8

1 reference

29 November 2017

language of work or name

1 reference

1 July 2002

1 reference

Journal of Neuroimmunology

29 November 2017

published in

1 reference

29 November 2017

volume

128

1 reference

29 November 2017

issue

1-2

1 reference

29 November 2017

page(s)

16-22

1 reference

The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

The CCR5 deletion mutation fails to protect against multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Chemokines and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Chemokine-based therapies for MS: how do we get there from here?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Chemokines--chemotactic cytokines that mediate inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Chemokine receptor antagonism as a new therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Early application of Met-RANTES ameliorates chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2802%2900121-2

7 January 2021

10.1016/S0165-5728(02)00121-2

Identifiers

DOI

1 reference

release_sy6r2c42zzeofmggihpnowzim4

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sy6r2c42zzeofmggihpnowzim4

24 November 2022

mapped directly with Wikidata item

1 reference